These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12431016)

  • 1. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute).
    Yeates C
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1446-52. PubMed ID: 12431016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
    Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J
    Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
    Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J
    Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 8-Aminoquinolines: future role as antiprotozoal drugs.
    Tekwani BL; Walker LA
    Curr Opin Infect Dis; 2006 Dec; 19(6):623-31. PubMed ID: 17075340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance.
    Loiseau PM; Cojean S; Schrével J
    Parasite; 2011 May; 18(2):115-9. PubMed ID: 21678786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
    Garnier T; Brown MB; Lawrence MJ; Croft SL
    J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model.
    Marley SE; Eberhard ML; Steurer FJ; Ellis WL; McGreevy PB; Ruebush TK
    Antimicrob Agents Chemother; 1997 Jan; 41(1):91-4. PubMed ID: 8980761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolines as chemotherapeutic agents for leishmaniasis.
    Reynolds KA; Loughlin WA; Young DJ
    Mini Rev Med Chem; 2013 Apr; 13(5):730-43. PubMed ID: 23469781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmaniasis: in search of new chemotherapeutic agents.
    Kinnamon KE; Steck EA; Loizeaux PS; Chapman WL; Waits VB; Hanson WL
    Am J Vet Res; 1980 Mar; 41(3):405-7. PubMed ID: 7369615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
    Ali A
    Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Talnetant GlaxoSmithKline.
    Evangelista S
    Curr Opin Investig Drugs; 2005 Jul; 6(7):717-21. PubMed ID: 16044668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes.
    López-Martín C; Pérez-Victoria JM; Carvalho L; Castanys S; Gamarro F
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4030-6. PubMed ID: 18794384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents.
    Cruz LJ; Luque-Ortega JR; Rivas L; Albericio F
    Mol Pharm; 2009; 6(3):813-24. PubMed ID: 19317431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral miltefosine to treat leishmaniasis].
    Soto J; Soto P
    Biomedica; 2006 Oct; 26 Suppl 1():207-17. PubMed ID: 17361856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miltefosine: oral treatment of leishmaniasis.
    Soto J; Soto P
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology evaluation: mepolizumab, GlaxoSmithKline.
    Gnanakumaran G; Babu KS
    Curr Opin Mol Ther; 2003 Jun; 5(3):321-5. PubMed ID: 12870444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of trypanosomiases and leishmaniasis.
    Croft SL; Barrett MP; Urbina JA
    Trends Parasitol; 2005 Nov; 21(11):508-12. PubMed ID: 16150644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
    Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.